Results 1 to 10 of about 5,687 (195)

BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. [PDF]

J Clin Oncol
Davids MS.
europepmc   +1 more source

Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma. [PDF]

Sci Adv
Zhang Y, Debaize L, Langenbucher A, Weekes J, Vogiatzi I, Miettinen TP, Zhang M, Sumpena E, Liu H, Duquette SM, Hackett L, Zhang J, Baghiyan S, Redd RA, Aryee M, Davids MS, Kim AI, Ryan CE, Weinstock DM, Manalis SR, Murakami MA.   +20 more
europepmc   +1 more source

A retrospective analysis of outpatient use of small-molecule targeted inhibitors for lymphoma across six regions of China (2016-2022). [PDF]

Front Pharmacol
Chen B, Chen LY, Chen P, Wang C, Yang CW, Hu Y, Wei R, Li LC, Fu ZL.   +8 more
europepmc   +1 more source

The Brief Case: Cutaneous ulceration associated with acalabrutinib treatment

Journal of Clinical Microbiology
Victor Luzarraga, Céline Nourrisson, Florence Anglade, Carole Chevenet, Philippe Poirier, Maxime Moniot   +5 more
doaj   +1 more source

Venetoclax Plus Rituximab for Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis of Treatments Available in Brazil. [PDF]

Oncol Ther
Barros BM, Costa MGS, Correia MG, Magliano CS, Lima PVP, Santoni NB, Duva A, Duran MI.   +7 more
europepmc   +1 more source

Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS). [PDF]

Ann Hematol
Quinquenel A, Leprêtre S, Dilhuydy MS, Bussot L, Marjanovic Z, Benbrahim O, Guièze R, Santagostino A, Dartigeas C, Feugier P, Roos-Weil D, Damaj G, Laribi K, Ysebaert L, Levy V.   +14 more
europepmc   +1 more source

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Blood
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA.   +26 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +1 more source

Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era. [PDF]

Int J Mol Sci
Allison E, Campbell A, Watson AM, Beaton B.   +3 more
europepmc   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source